Placebo News and Research

RSS

New study does not support hypertensive effect from urate elevation

A study from a group of Massachusetts General Hospital investigators may reduce the concern that elevating levels of urate, an approach being investigated to treat several neurodegenerative disorders, could increase the risk of hypertension.

8 Nov 2018

Exploring why some athletes ice their muscles after exercise

We've all seen it, after a gruelling and physical rugby many athletes plunge themselves into a bath of icy cold water or even in a cold air chamber, a treatment known as cryotherapy.

8 Nov 2018

Cholesterol-lowering drug reduces chance of having second heart problems or stroke

In a clinical trial involving 18,924 patients from 57 countries who had suffered a recent heart attack or threatened heart attack, researchers at the University of Colorado Anschutz Medical Campus and fellow scientists around the world have found that the cholesterol-lowering drug alirocumab reduced the chance of having additional heart problems or stroke.

8 Nov 2018

Cannabinoids hold promise in treating children with epilepsy

In recent years, cannabinoids--the active chemicals in medical marijuana-- have been increasingly touted as a potential treatment for a range of neurological and psychiatric disorders. In a Developmental Medicine & Child Neurology review, investigators compare their efficacy with antiepileptic drugs for children with epilepsy.

7 Nov 2018

New heart drug spotlights troubling trends in drug marketing

At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease.

2 Nov 2018

Drug combination not more effective in improving depression than single antidepressant

Psychiatrists and GPs increasingly combine mirtazapine with an SSRI (selective serotonin reuptake inhibitor) or SNRI (serotonin-noradenaline reuptake inhibitor) antidepressant for patients whose depression does not respond to a single antidepressant.

1 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

Ark Biosciences, a biotech company developing proprietary therapeutics for viral infection and respiratory diseases, announced today the significant progress in its phase 2 proof-of-concept study of ziresovir in the treatment of hospitalized RSV infected infants.

1 Nov 2018

World’s first vaccine against coeliac disease to be tested in Australia

US-based pharmaceutical company ImmusanT, after worldwide trials, is all set to start clinical trials of a new vaccine against coeliac disease at the Royal Melbourne Hospital Clinical Trials Centre in Melbourne. This will be followed by trials to be held at Adelaide, Brisbane, Perth, Mackay and Sunshine Coast say the sources.

31 Oct 2018

Using genome editing to prevent sudden cardiac death

Each year, at least 3 million people worldwide die of sudden cardiac death. In the U.S., this number reaches up to 450,000 people.

30 Oct 2018

PrEP shown to be safe and effective for widespread use

New research presented at the HIV Drug Therapy Conference in Glasgow today shows that pre-exposure prophylaxis could be given to millions of people worldwide with no increased risk of safety issues during treatment.

30 Oct 2018

Investigational drug targeting the opioid system may help reduce symptoms of major depression

Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms of major depression, when added to standard antidepressant treatment.

29 Oct 2018

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

29 Oct 2018

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.

29 Oct 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

High-impact clinical trial results could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2018 October 23-October 28 at the San Diego Convention Center.

26 Oct 2018

Quadrant Biosciences announces collaboration on research into treatment of ASD

Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network and its university research partners on research into the treatment of autism spectrum disorder.

26 Oct 2018

New flu drug Xofluza approved - FDA emphasizes importance of flu shots

A new drug that works against flu has been developed and has been approved by the Food and Drug Administration (FDA) yesterday (24th October 2018). Until now the only drug available for flu is oseltamivir (Tamiflu) which is to be administered by two pills per day for five days after symptoms appear.

25 Oct 2018

FDA approves new antiviral flu treatment

Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

24 Oct 2018

Novel drug extends survival for women with HR-positive metastatic breast cancer

The drug palbociclib, used in combination with standard treatment, improved survival for women with hormone receptor-positive metastatic breast cancer, according to a large phase III clinical trial.

24 Oct 2018

Placebo News and Research

New study does not support hypertensive effect from urate elevation

Exploring why some athletes ice their muscles after exercise

Cholesterol-lowering drug reduces chance of having second heart problems or stroke

Cannabinoids hold promise in treating children with epilepsy

New heart drug spotlights troubling trends in drug marketing

Drug combination not more effective in improving depression than single antidepressant

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

World’s first vaccine against coeliac disease to be tested in Australia

Using genome editing to prevent sudden cardiac death

PrEP shown to be safe and effective for widespread use

Investigational drug targeting the opioid system may help reduce symptoms of major depression

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

High-impact clinical trial results could affect kidney-related medical care

Quadrant Biosciences announces collaboration on research into treatment of ASD

New flu drug Xofluza approved - FDA emphasizes importance of flu shots

FDA approves new antiviral flu treatment

Novel drug extends survival for women with HR-positive metastatic breast cancer

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News